“Biologics have become an important tool in the treatment of asthma and other allergic diseases such as atopic dermatitis [eczema], chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis, and can prevent substantial ill results from occurring in patients who are eligible for them,” Ca...
While safety and efficacy of these drugs has been proven extensively in clinical trials, these drugs possess the potential for cutaneous as well as systemic toxicity owing to their immunosuppressive effects. This book chapter focuses on the adverse cutaneous reactions observed with biologics, ...
(AS) and adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is a biologic. A biologic is a protein-based drug produced from living cells. Different from traditional systemic drugs that impact the entire immune system, biologics target ...
to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical...
The signals we have detected will be examined for validity using the same robust analytical pipeline in PSORT, which we show is substantially powered to detect true biomarkers of response to therapy. Likewise, as omics techniques are applied to other dermatological diseases such as atopic eczema (...
Eczema: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia). Asthma: injection site reactions, hi...
Sinclair. “Clinical trials are currently underway to assess a further three new agents for the treatment of psoriasis.” These include seven trials enrolling Australians with psoriasis who would like to be involved in testing the new drugs (see table at the bottom of this article for details)....
eczemaBiologic medications are recent advances that have clinical significance in the treatment of moderate-to-severe AD. A systemic literature review was performed to examine the efficacy and safety of biologic therapies currently in phase II and phase III of clinical trials for moderate-to-severe ...
Food and Drug Administration for the disease, yet there are many deterrences in collecting the important data. She added that she will recommend interfeon gamma, instead of methotrexate, cyclosporine or azathioprine, if there is an evidence of infection of eczema he...